F-10POS: Oncolytics Biotech Deregisters Unsold Securities
Deregistration of Securities
Oncolytics Biotech Inc. is filing post-effective amendments to deregister unsold securities from multiple previous registration statements.
Summary
- Oncolytics Biotech Inc. has filed post-effective amendments to several Form F-10 registration statements.
- The purpose of these amendments is to withdraw and deregister any unsold portions of securities that were previously registered.
- These actions pertain to various offerings including units, common shares, subscription receipts, warrants, and debt securities.
- The company is certifying that it meets all requirements for filing on Form F-10.
- The effective date for this filing is set for April 16, 2026, at 4:30 p.m. Eastern time.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to its administrative nature and the implication that past offerings did not fully sell their registered securities, though it is not indicative of current company health.
Future Outlook
The filing does not contain forward-looking statements or guidance; it pertains to the deregistration of previously registered but unsold securities.
Industry Context
StockSavvy.ai notes that this filing is a procedural administrative action by Oncolytics Biotech to clean up its historical SEC filings by removing registrations for securities that were never issued or sold. This is a common practice for companies that have completed or terminated past offerings and does not reflect current operational or financial performance.
Stakeholder Impact
- Shareholders: No direct impact on current share value or holdings, as this relates to previously registered but unsold securities.
Next Steps
- The post-effective amendments will become effective on April 16, 2026.
- Unsold securities registered under the referenced statements will be deregistered.
Key Dates
| Date | Description |
|---|---|
| February 5, 2007 | Initial filing date for Registration Statement No. 333-140460. |
| February 8, 2007 | Initial filing date for Registration Statement No. 333-140529. |
| June 6, 2008 | Initial filing date for Registration Statement No. 333-151513. |
| June 2, 2010 | Initial filing date for Registration Statement No. 333-167250. |
| June 21, 2012 | Initial filing date for Registration Statement No. 333-182260. |
| July 25, 2014 | Initial filing date for Registration Statement No. 333-197633. |
| April 25, 2018 | Initial filing date for Registration Statement No. 333-224432. |
| June 8, 2020 | Initial filing date for Registration Statement No. 333-239025. |
| June 10, 2022 | Initial filing date for Registration Statement No. 333-265510. |
| July 25, 2024 | Initial filing date for Registration Statement No. 333-281009. |
| April 8, 2026 | Date of filing of post-effective amendments and signing of the document. |
| April 16, 2026 | Proposed effective date for the post-effective amendments at 4:30 p.m. Eastern time. |
Keywords
Oncolytics Biotech, SEC Filing, Form F-10, Registration Statement, Deregistration, Securities, Post-Effective Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.